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against HBV is highly cost-effective in Viet Nam. As a low-income, endemic country 
where funds are limited and economic results of vaccination are uncertain, afford-
ability options allow decision-makers to make proper health investment in vaccination 
strategies against HBV. In the long run, adolescents should also be universally vac-
cinated against HBV. 
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OBJECTIVES: To assess the cost-effectiveness of mobile phone “contact-reminder” 
compared to self-administered treatment (SAT) to control tuberculosis (TB) in Thai-
land. METHODS: Cost-effectiveness analysis was undertaken using a decision tree 
model, which included three stages of treatment; initial treatment, re-treatment, and 
multi-drug resistant TB treatment. Costs (2005 international dollars: I$) were calcu-
lated based on treatment periods and treatment outcomes. Health outcomes were 
estimated over the lifetime of smear-positive pulmonary TB patients in disability-
adjusted life-years (DALYs). Both costs and health outcomes were discounted 3% 
annually. Mobile phone reminders are a relatively new TB treatment strategy. A pilot 
study reported a mortality rate far higher than observed using other strategies, but 
there were reasons to suspect this was inﬂ uenced by the high age and comorbidities 
of the trial sample. We undertook a sensitivity analysis using mortality rates observed 
during other treatment strategies, to indicate if mobile phone reminders could be 
cost-effective in Thailand. RESULTS: Sensitivity analysis showed lowering the mortal-
ity rate to values observed in trials of other treatment strategies made the mobile phone 
reminder intervention more cost-effective than SAT, as a result of an increase in the 
DALYs averted. Using the highest (8%) and the lowest (3%) death rates from the 
other TB control strategies, the probability that the mobile phone intervention was 
more cost-effective than SAT was 98% and 100%, respectively. CONCLUSIONS: If 
further trials show the mortality rate using a mobile phone reminder system to be 
similar to that observed under other treatment strategies, this strategy would be more 
cost-effective than SAT. A bigger study with control group and proper age distribution 
is needed to examine the true merits of mobile phone intervention. 
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OBJECTIVES: To assess the comparative costs and outcomes of HIV treatment 
algorithms with and without the use of raltegravir for treatment naïve patients. 
METHODS: A cost-utility analysis was constructed using a Markov model to assess 
the incremental cost per QALY gained of a HIV treatment algorithm which included 
raltegravir as a ﬁ rst line treatment compared to standard practice in Australia. Com-
parator treatment algorithms were constructed for patients initiating treatment with 
a non-nucleoside reverse transcriptase inhibitor (NNRTI) containing regimen and 
patients initiating treatment with a protease-inhibitor (PI) containing regimen. The 
economic model was a Markov cohort model with the cohort transited through ﬁ ve 
health states which reﬂ ect four lines of the treatment in each algorithm and death. 
The modeled population cycled through the treatment algorithm upon loss of virologic 
response and at each cycle are at risk of adverse events, AIDS events and death based 
on the treatment regimen received, viral load and CD4 count. The efﬁ cacy and safety 
of each treatment at each line of the algorithm was based on randomized clinical trial 
data and a mixed treatment comparison. Costs were calculated from the perspective 
of the Australian health-care system. The economic model was a lifetime model. 
RESULTS: The raltegravir algorithm was more costly than the NNRTI algorithm 
(A$4487 per patient) but less costly than the PI algorithm (A$18,383 per patient). 
The raltegravir algorithm had greater QALYs than both the comparator algorithms 
(0.17 and 0.22 per patient compared to the NNRTI and PI algorithms respectively). 
The incremental cost per QALY of the raltegravir algorithm compared to the NNRTI 
regimen was A$26,896 which is considered within an acceptable threshold in Austra-
lia. The raltegravir algorithm dominated the PI algorithm (lower costs and greater 
QALYs). CONCLUSIONS: Raltegravir for treatment naïve patients is an effective and 
cost-effective intervention relative to current practice in Australia. 
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OBJECTIVES: To assess the cost-effectiveness of daptomycin versus glycopeptides 
(vancomycin and teicoplanin), the most widely used alternatives in the treatment of 
patients with infective endocarditis and bacteremia caused by Methicillin resistant 
Staphylococcus Aureus (MRSA) from the perspective of Turkish health-care system. 
METHODS: The clinical trials with daptomycin were powered to show non-inferior-
ity against vancomycin. The model is based on a cost-minimization analysis, assuming 
similar efﬁ cacy between daptomycin and glycopeptides. However, median length of 
inpatient treatment, hence hospital stay differed among therapies in the trial. A 
decision-analytic model was designed to estimate the use of resources and costs based 
on treatment duration and patterns. The model time horizon was from the ﬁ rst day 
of the hospitalization to successful treatment. Resource utilization was collected from 
literature and complemented with the help physician survey in Turkey. Resource use 
consisted of drug costs, iv and im administration costs, monitoring and hospitalization 
costs. Key parameters and assumptions in the model were explored in sensitivity 
analyses to determine their impact on the model outcome. RESULTS: The use of 
daptomycin as ﬁ rst-line therapy resulted in lower cost per patient despite signiﬁ cant 
daily drug cost difference between alternatives. Total health-care costs per patient were 
f2069 for the daptomycin whereas f2392 and f2419 for the vancomycin and teico-
planin arms respectively, resulting in f323-f350 savings per person with daptomycin 
treatment. The main cost driver was drug costs, which was responsible for 66% of 
the total costs on average. CONCLUSIONS: Daptomycin is less costly than both 
vancomycin and teicoplanin in the treatment of MRSA induced bacteremia and infec-
tive endocarditis when used as ﬁ rst-line therapy. The cost-savings with daptomycin in 
Turkey largely stem from shorter treatment duration with daptomycin due to its highly 
effective and rapid bactericidal activity. 
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OBJECTIVES: To assess the value for money of introducing three-drug antiretroviral 
regimens, namely 1) zidovudine—AZT, lamivudine—3TC, and efavirenz—EFV; or 2) 
AZT, 3TC, and lopinavir/ritonavir—LPV/r, in comparison to the current protocol, 
AZT plus single-dose nevirapine–sd-NVP, for the prevention of mother-to-child trans-
mission (PMTCT) of HIV in Thailand. METHODS: A decision tree was constructed 
to predict costs and outcomes using the Thai governmental perspective. The costs 
consisted of 1) program costs; 2) costs of treatment of premature birth; 3) costs of 
treatment of pediatric HIV infection; and 4) costs of treatment of drug resistance 
among mothers. All costs were presented in 2009 Thai baht. The outcome was mea-
sured in terms of quality-adjusted life-years (QALYs) gained from infant HIV infection 
averted. The costs and outcomes were discounted with the rate of 3% as recommended 
by the national guidelines. RESULTS: Introduction of the three-drug antiretroviral 
regimens yields lower costs and better health outcomes compared to AZT + sd-NVP. 
Although these three-drug regimens offer higher program costs and health-care costs 
for premature birth, they signiﬁ cantly save money in regard to pediatric HIV treatment 
and treatment costs for drug resistance in the mothers. In addition, approximately 1 
QALY is averted as a result of using the regimens. Because of the lack of clinical 
evidence to distinguish the difference in terms of PMTCT efﬁ cacy between EFV-based 
and LPV/r-based regimens, the analysis favors a cheaper EFV-based regimen. Results 
from univariate uncertainty analysis also support the above conclusion and a tornado 
diagram presents the relative importance of each model input parameter. CONCLU-
SIONS: The three-drug regimens are cost-saving for PMTCT in Thailand, and ﬁ ndings 
from this study support a change in the National PMTCT guidelines in the country. 
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OBJECTIVES: In Indonesia, legislation mandates a medical prescription for purchase 
of antibiotics. However, the use of nonprescribed antibiotics is widespread among the 
population. Therefore, the aim of this study was to elicit common beliefs about the 
use of antibiotics without prescription among Indonesians in an urban area of Yog-
yakarta. METHODS: Adults (>18 years old) with experience of using nonprescribed 
antibiotics, including leftovers from previously prescribed medication were inter-
viewed. The questions focused on the advantages, disadvantages, enabling factors and 
social pressure related to this behavior. Two researchers independently analyzed the 
qualitative data using thematic analysis. RESULTS: A total of 25 face to face inter-
views has been conducted. Saving money and saving time—as a result of avoiding a 
medical consultation—were two main advantages of using nonprescribed antibiotics. 
Moreover, this behavior was reported as preventing the participants from taking too 
many different types of medicines commonly prescribed by doctors. Despite insurance 
coverage for the cost of prescribed medicines and medical consultation fees, some 
participants preferred to purchase nonprescribed antibiotics out-of-pocket because of 
the perceived advantages mentioned. Availability of antibiotics to be purchased 
without prescription in pharmacies as well as their accessibility in shops, and previous 
